Ligand Pharmaceuticals Incorporated
LGND
$159.86
$1.070.67%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 47.63M | 45.33M | 42.81M | 51.81M | 41.53M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 47.63M | 45.33M | 42.81M | 51.81M | 41.53M |
| Cost of Revenue | 9.47M | 54.93M | 7.26M | 8.12M | 8.26M |
| Gross Profit | 38.15M | -9.60M | 35.55M | 43.69M | 33.27M |
| SG&A Expenses | 20.18M | 18.80M | 25.61M | 24.48M | 17.62M |
| Depreciation & Amortization | 8.26M | 8.26M | 8.26M | 8.26M | 8.26M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 37.91M | 81.99M | 41.13M | 40.86M | 34.14M |
| Operating Income | 9.72M | -36.66M | 1.69M | 10.96M | 7.39M |
| Income Before Tax | 11.22M | -50.18M | -39.20M | -6.34M | -65.39M |
| Income Tax Expenses | 6.38M | -7.73M | -8.11M | 833.00K | -13.48M |
| Earnings from Continuing Operations | 4.85M | -42.45M | -31.09M | -7.17M | -51.91M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 4.85M | -42.45M | -31.09M | -7.17M | -51.91M |
| EBIT | 9.72M | -36.66M | 1.69M | 10.96M | 7.39M |
| EBITDA | 17.82M | -28.35M | 10.31M | 19.95M | 16.24M |
| EPS Basic | 0.25 | -2.21 | -1.64 | -0.39 | -2.88 |
| Normalized Basic EPS | 0.33 | -1.23 | 0.48 | -0.30 | 0.24 |
| EPS Diluted | 0.24 | -2.21 | -1.64 | -0.39 | -2.88 |
| Normalized Diluted EPS | 0.32 | -1.23 | 0.48 | -0.30 | 0.24 |
| Average Basic Shares Outstanding | 19.33M | 19.19M | 18.97M | 18.42M | 18.03M |
| Average Diluted Shares Outstanding | 19.93M | 19.19M | 18.97M | 18.42M | 18.03M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |